The candidatureof the HSP90 chaperone protein inhibitors was deemed suitable forthe tetheration to the structural template of Tazemetostat, in lightof numerous reports validating the efficacy of HSP90 inhibitors inGBM coupled with our preliminary investigation results confirmingthe possible attainment of remarkable anti-GBM efficacy through acombination of EZH2 and HSP90 inhibitors. The gene discussed is HSP90AA1; the disease is glioblastoma.